Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 4, 2003. The report details a specific corporate action regarding share re-purchases authorized by shareholders at the Annual General Meeting held on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 790,000 ordinary shares
- Purchase Price: 1,261.64p per share
- Transaction Date: June 4, 2003
- Use of Proceeds: Shares were purchased for cancellation
Material Changes
The filing does not disclose material changes in revenue, operating results, or financial position compared to prior periods. The primary change reported is the reduction of the company's share capital through the cancellation of 790,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a notification of the execution of the share buyback program.
Key Facts for Investor Verification
- Verify the total number of shares authorized for re-purchase at the May 19, 2003 Annual General Meeting to determine the remaining buyback capacity.
- Confirm the total cost of the transaction (790,000 shares x 1,261.64p) against the company's cash reserves or debt facilities.
- Check subsequent filings to track the progress of the share cancellation and its impact on earnings per share.